Dr. Reddy's
E-Mail: You need to be a registered (and logged in) user to view Dr. Reddy's email address
Total Articles : 4
Click here to submit Post PR News
Dr. Reddy’s Laboratories announces the launch of Pregabalin Capsules in the U.S. Market
Hyderabad, India and Princeton, NJ, USA. July 30, 2019 — Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Pregabalin Capsules a therapeutic equivalent →
0 Views : 1075
Dr. Reddy’s Laboratories announces the launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules in the U.S. Market
Hyderabad, India and Princeton, NJ, USA. June 22, 2019— Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Phytonadione Injectable Emulsion USP, 10 mg/ml →
0 Views : 830
Dr. Reddy’s Laboratories announces the launch of Tobramycin Inhalation Solution, USP in the U.S. Market
Hyderabad, India and Princeton, NJ, USA. June 25, 2019 — Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Tobramycin Inhalation Solution, USP a →
0 Views : 774
Dr. Reddy’s Laboratories Limited announces filing of Annual Report on Form 20-F
Hyderabad, India, June 16, 2018 Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2018 was filed →
0 Views : 979
